// App-Quantinova.ai

423.0 : Alpha fetoprotein (AFP) response and efficacy outcomes in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).

Researchers

Presenter

  • Robin Kate Kelley

Principal Investigators

  • Lorenza Rimassa

  • Baek-Yeol Ryoo

  • Joong-Won Park

  • Jean-Frdric Blanc

  • Stephen Lam Chan

  • Vincenzo Dadduzio

  • Thomas Cheung Yau

  • Suvajit Sen

  • David W. Markby

  • Rajesh Kaldate

  • Anthony B. El-Khoueiry

  • Ann-Lii Cheng

  • Tim Meyer

  • Ghassan K. Abou-Alfa

Medical Centers

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Humanitas Clinical and Research Center, Rozzano, Italy

  • Surgery, , Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of

  • National Cancer Center Korea, Goyang-Si, Korea, Republic of (South)

  • Service dHepato-Gastroenterologie et dOncologie Digestive, Groupe Hospitalier Saint Andre, Bordeaux, France

  • Department of Clinical Oncology, State Key Laboratory of Oncology in South China, The Chinese University of Hong Kong, Hong Kong, Hong Kong

  • Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy

  • Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong

  • Exelixis, Alameda, CA

  • USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA

  • National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan

  • University College London Hospitals/UCL Cancer Institute, London, United Kingdom

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

  • Italy

  • France

  • Hong Kong

  • Taiwan

  • United Kingdom

  • Republic of South Korea

Companies

  • Exelixis, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • Alpha-fetoprotein

Drug/Treatment

  • Cabozantinib

  • Sorafenib

Outcome

  • N/A


Study Design

  • Randomized

  • Placebo Control

  • Prospective

Phase

  • NA

Study Id's

  • NCT01908426

Sponsors

  • N/A

Result

  • N/A